Chicago Equity Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Chicago Equity Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$450K	Buy	9,923 +529	+6%	+$30K	0.05%	455
2019 Q4	$611K	Buy	9,394 +586	+7%	+$39.2K	0.04%	594
2019 Q3	$547K	Sell	8,808 -6,148	-41%	-$386K	0.03%	660
2019 Q2	$1.06M	Sell	14,956 -30,914	-67%	-$2.28M	0.05%	509
2019 Q1	$3.6M	Buy	45,870 +4,761	+12%	+$361K	0.14%	202
2018 Q4	$3.48M	Buy	41,109 +2,605	+7%	+$278K	0.14%	204
2018 Q3	$6.59M	Buy	38,504 +11,894	+45%	+$1.79M	0.19%	147
2018 Q2	$3.44M	Buy	26,610 +1,908	+8%	+$213K	0.11%	284
2018 Q1	$2.54M	Buy	+24,702	New	+$2.44M	0.08%	329

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Equity Partners's LGND Position: Q1 2020 in Review

Chicago Equity Partners increased its Ligand Pharmaceuticals (LGND) stake by 5.6% in Q1 2020, buying an estimated $30K and bringing the position to 9,923 shares worth $450K. The position accounts for 0.05% of the portfolio, ranked #455.

Chicago Equity Partners first reported a position in LGND in Q1 2018 and has held it in 9 quarters since. The position peaked at $6.59M in Q3 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

Chicago Equity Partners held 9,923 shares of Ligand Pharmaceuticals worth $450K as of Q1 2020.
Chicago Equity Partners bought 529 Ligand Pharmaceuticals shares in Q1 2020, an estimated $30K.
Ligand Pharmaceuticals made up 0.05% of Chicago Equity Partners's portfolio in Q1 2020, its #455 holding.
Chicago Equity Partners first reported a position in Ligand Pharmaceuticals in Q1 2018 and has held it in 9 quarters since.
Chicago Equity Partners's Ligand Pharmaceuticals position peaked at $6.59M in Q3 2018.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.